Hollings Renton sold $201k of ANAB
director at ANAPTYSBIO, INC. 10,231 shares at an average of $19.62, traded Aug 8, 2025, filed Aug 12, 2025.
Score components
- +15RoleDirector
- +12Trade size$201k at market
- +20Share of holdings soldSold 67% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-021486, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 8, 2025 | MOption exercise Common Stock10b5-1 | +10,231 | $6.93 | $71k | 15,196 | Aug 12, 2025 |
| Aug 8, 2025 | SOpen-market sale Common Stock10b5-1 | -3,110 | $19.44 | $60k | 12,086 | Aug 12, 2025 |
| Aug 8, 2025 | SOpen-market sale Common Stock10b5-1 | -7,121 | $19.70 | $140k | 4,965 | Aug 12, 2025 |
| Aug 8, 2025 | MOption exercise Common Stockderivative10b5-1 | -10,231 | $0.00 | $0 | 0 | Aug 12, 2025 |
Related signals
Other insiders at ANAPTYSBIO, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | ANAPTYSBIO, INC | Hollings Renton director | $249k 5,000 shares | -31% | |
| 33Weak | ANAPTYSBIO, INC | Eric J Loumeau CHIEF LEGAL OFFICER | $510k 10,000 shares | -53% | |
| 40Moderate | ANAPTYSBIO, INC | Dennis Mulroy CHIEF FINANCIAL OFFICER | $500k 10,000 shares | -52% | |
| 3Weak | ANAPTYSBIO, INC | Paul F. Lizzul Chief Medical Officer | $75k 1,500 shares | -5% | |
| 52Moderate | ANAPTYSBIO, INC | J. Anthony Ware director | $193k 3,900 shares | -29% | |
| 40Moderate | ANAPTYSBIO, INC | Eric J Loumeau CHIEF LEGAL OFFICER | $1.0M 22,641 shares | -105% | |
| 43Moderate | ANAPTYSBIO, INC | Dennis Mulroy CHIEF FINANCIAL OFFICER | $705k 15,725 shares | -63% | |
| 3Weak | ANAPTYSBIO, INC | Eric J Loumeau CHIEF LEGAL OFFICER | $239k 8,240 shares | -48% | |
| 26Weak | ANAPTYSBIO, INC | Hollings Renton director | $493k 20,925 shares | -81% | |
| 21Weak | ANAPTYSBIO, INC | Hollings Renton director | $72k 3,015 shares | -38% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.